NCT00437424

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

A Pharmacokinetic Study of Brivanib (BMS-582664) in Subjects With Advanced Solid Tumor Malignancies and Normal Hepatic Function or Hepatocellular Carcinoma With Impaired Hepatic Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this protocol is to determine the effect of BMS-582664 on patients with hepatocellular carcinoma with varying levels of hepatic impairment

Conditions

• Carcinoma, Hepatocellular

Interventions

Type	Name	Description
DRUG	Brivanib	Tablet, Oral, Brivanib 400 mg, based on Day 1 PK, QD, until progression

Timeline

• Start date: 2007-07-01
• Primary completion: 2010-06-01
• Completion: 2010-06-01
• First posted: 2007-02-21
• Last updated: 2011-05-04

Locations

5 sites across 2 countries: United States, Spain